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Heart failure (HF) is a state in which cardiac functioning fails to meet the oxygen and 
nutrient demands required by the body to maintain its normal function. It is a clinical 
syndrome characterized by symptoms like shortness of breath, leg swelling and exercise 
intolerance. For a person aged 55 years, the lifetime risk of developing HF is about 30%.1 
In the adult population, 1-2% has HF, but it mainly affects the elderly; 6-10% of people 
aged 65 or older have HF.2 Due to the aging population in (Western) countries, the 
prevalence is expected to double within the next 40 years.
Despite modern treatments, the condition usually worsens over time. Unfortunately, 30 
to 40% of patients diagnosed with HF die within one year after receiving the diagnosis 
and 60-70% die within 5 years.3 This makes HF more lethal than some common forms of 
cancer.4 HF patients die from worsening HF or sudden cardiac death due to ventricular 
arrhythmia’s. 
Heart failure currently has no cure; treatment focuses on improving symptoms and pre-
venting acute decompensation or disease progression. This is achieved by addressing 
reversible causes such as valvular anomalies, providing lifestyle education and treat-
ments using pharmacological agents or devices.5 It is recommended that all HF patients 
with a reduced ejection fraction receive first-line therapy consisting of angiotensin 
converting enzyme inhibitors (ACE inhibitors), or when not tolerated angiotensin II re-
ceptor blockers (ARBs), and β-blockers. In still symptomatic patients, mineralocorticoid 
receptor antagonists are added to this regime.  Diuretics are used to treat symptoms 
and congestion.5 There are far less options for patients with HF with a preserved ejec-
tion fraction. No treatment has yet been shown, convincingly, to reduce morbidity or 
mortality in this population. Currently, treatment consist of diuretics to alleviate signs 
and symptoms, and the screening and treatment of comorbidities.
comorbidities
An essential part of the management of HF, either with a reduced or preserved ejec-
tion fraction, concerns the diagnosis and treatment of comorbidities. Of all HF patients 
older than 65 years, 98% have at least one comorbidity.6-8 Two prevalent comorbidities 
contribute directly to the already impaired peripheral oxygen delivery: iron deficiency 
and anemia. First considered cause and consequence, recent results, including ours, 
have shown that both have to be considered as separate entities.
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ANemIA
Anemia is defined by the WHO as a hemoglobin level of <12g/dL (~7.5mmol/L) in 
women and <13g/dL (~8.1mmol/L) in men.9 Worldwide, the prevalence of anemia is 
32.9%, with especially high prevalence’s in sub-Saharan Africa and south-east Asia.10 
In chapter 2, we discuss anemia in the context of the HF patient; we describe the 
pathophysiology and focus on the results of clinical trials aimed at correcting anemia 
and promising future therapies. The majority of therapies developed for anemia in HF 
comprise drugs targeting erythropoiesis, mainly through its hormonal stimulation, for 
instance by the administration of recombinant erythropoietin (EPO).
endogenous ePo
Erythropoietin is the primary regulator of erythropoiesis; in the bone marrow, EPO 
promotes the proliferation of erythroid progenitor cells and increases the production of 
red blood cells.11,12 While normally erythropoiesis takes place at a low basal rate, EPO is 
capable of enhancing production as much as eightfold compared to the baseline rate. 
Eighty percent of EPO is produced in the kidney in reaction to impaired oxygen delivery, 
the remaining mostly being produced in the liver.13 To allow for interpretation of EPO 
levels, we were interested in the normal values, physiological function and regulation 
of human EPO. In chapter 3, we study endogenous EPO levels in a large sample of the 
general population of Groningen. 
High levels of endogenous EPO are frequently observed in patients with HF.14-16 The 
etiology of the elevated EPO levels in HF is multifactorial, but includes direct stimulation 
of EPO synthesis by renal hypoxia, bone marrow resistance to EPO and increased angio-
tensin II concentrations.17-19 Previous studies showed that the endogenous EPO level is 
a prognostic marker in patients with chronic HF.14,20 It is currently unknown if EPO levels 
are also associated with the incidence of new onset HF. We study the association of 
endogenous EPO levels with the development of new onset HF and other cardiovascular 
events in chapter 4.
exogenous ePo
Anemia can successfully be corrected in the majority of HF patients using a recombinant 
form of EPO.21,22 One of these drugs, darbepoetin-alfa was studied in the randomized, 
blinded clinical trial the reduction of events with darbepoetin alfa in heart failure trial 
(RED-HF).21 In this trial, 2,278 patients with symptomatic chronic HF (LVEF ≤ 40%) and 
anemia (HB level 9.0 to 12.0 g/dL) were treated with darbepoetin-alfa with a target 
hemoglobin level of 13.0 to 14.5 g/dL or placebo. Disappointingly, this approach did not 
result in a better prognosis. In contrast, rates of stroke and thromboembolic events were 
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Chapter 1
increased in patients treated with darbepoetin-alfa, halting the clinical use of recom-
binant EPO in HF patients. Despite these consequences, patients with chronic kidney 
disease still often use recombinant EPO to prevent the need for blood transfusion. It is 
known that approximately 25% of chronic kidney disease patients are poor responders, 
that is a low hemoglobin increase in response to darbepoetin-alfa.23 This low response 
is associated with increased mortality.23 Since the syndromes of HF and chronic kidney 
disease show large overlap, we study the hematological response to darbepoetin-alfa in 
the large randomized controlled RED-HF trial in chapter 5.
IroN defIcIeNcy
Next to erythropoietin, iron is an essential factor in the successful production of a red 
blood cell. A deficiency in iron often leads to anemia, and many of the consequences 
seen in patients with iron deficiency were thus attributed to anemia. However, data 
showed that iron deficiency is, independent from the presence of anemia, associated 
with more signs and symptoms and an increased morbidity and mortality in patients 
with HF.24,25 New, safer, iron preparations boosted research in this area and clinical trials 
showed that treatment with intravenous iron improved signs and symptoms of HF in 
iron deficient subjects.26-31 Iron deficiency is present in 30 – 72% of the HF population, 
depending on its definition and HF severity.24,32,33 The gold standard of the diagnosis of 
iron deficiency is a Prussian blue staining of a bone marrow aspirate. This procedure is 
invasive, painful and time-consuming. In clinical care, but also in research, a definition 
based on serum biomarkers is therefore used but never validated. Based on data from 
healthy subjects and other chronic diseases a combination between ferritin and trans-
ferrin saturation (TSAT) is often used. However, ferritin is an acute phase reactant and 
therefore increased in varying degrees in subjects with HF, depending on the severity of 
the low grade inflammation. In chapter 6, we study bone marrow aspirates in relation 
with circulating biomarkers in patients with HF to provide an optimal definition of iron 
deficiency. We subsequently study this definition in two different clinical settings to 
assess effects on morbidity, mortality and treatment effect. The additional benefit of a 
bone marrow iron staining is the possibility to assess the pathophysiology of the iron 
deficit. We can quantify the amount of iron stored in the bone marrow and the actual 
amount of iron incorporated in the erythroblasts, the precursors of the red blood cells. 
Using this method, we assess if iron deficient patients have low iron stores or if they 
have defective iron utilization. We study these different pathophysiological mechanisms 
in chapter 7. 
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Iron has more functions besides hematopoiesis. Iron can switch between its ferrous 
(Fe2+) and ferric (Fe3+) form, which gives it the ability to mediate electron transfer, and 
play a vital role in many redox reactions. Mitochondria rely in their function of ATP pro-
duction on these redox reactions. The mitochondrial electron transport chain complexes 
I-V contain iron-sulfur clusters, heme and cytochromes. Complexes I, III and IV facilitate 
the redox reactions required to pump H+ outside the inner membrane. The result is 
an electrochemical gradient which is used to drive complex V: an ATP synthase which 
generates ATP from ADP by oxidative phosphorylation. Cells that require a high energy 
demand, such as the cardiomyocytes and skeletal myocytes, are rich in mitochondria. 
Therefore, potential detrimental effects of iron deficiency are expected in these cell 
types. We study the effects of iron deficiency on mitochondrial function, cell metabolism 
and contractile function in the human cardiomyocyte in chapter 8.
Aims of this thesis
The aim of this thesis is to evaluate the role of the major factors in oxygen transport and 
utilization in patients with heart failure. These factors include erythropoietin, hemoglo-
bin and iron. 
In part I, we study erythropoietin and anemia. In chapter 2, we discuss the patho-
physiology of anemia in heart failure, review treatments that have been studied and why 
some have failed and mention potential new treatments. We study erythropoietin in the 
general population in chapter 3. We provide reference values and report on clinical 
and biochemical correlates. Additionally, we provide a novel genetic variant associated 
with erythropoietin levels. chapter 4 elaborates on this work by assessing associa-
tions between endogenous erythropoietin levels and new onset HF and cardiovascular 
events. In chapter 5, we study the treatment of anemia with recombinant erythropoi-
etin. We assess the increase in hemoglobin concentration in reaction to treatment with 
recombinant erythropoietin, define a group of hypo-responsive subjects and study its 
consequences.
In part II of this thesis, we focus on the role of iron, and specifically iron deficiency in 
HF. In chapter 6 we start defining iron deficiency in HF by using the gold standard for 
ID: bone marrow aspirations.  We assess the value of different circulating biomarkers 
of iron status in HF patients and compare them to the gold standard. Using the same 
bone marrow aspiration data, we asses in chapter 7 two distinct pathophysiological 
mechanisms of iron deficiency: low iron stores and defective iron utilization. In chapter 
8, we study the direct effects of iron deficiency on the human cardiomyocyte. In chapter 
9, we assess potential causality between iron levels coronary artery disease, the most 
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Chapter 1

Part I
Anemia and erythropoietin

